Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.

Schiavon M, Visentin R, Göbel B, Riz M, Cobelli C, Klabunde T, Dalla Man C

Diabetes, obesity & metabolism5 May 2021Cited by 42 (Europe PMC)

PMID33822469PMCIDPMC8359969DOI10.1111/dom.14394PepBankPUB-33822469

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight to obese adults with type 2 diabetes, liraglutide significantly improved basal insulin action by a median 35% from baseline to end of treatment.
In plain wordsIn overweight or obese adults with type 2 diabetes, liraglutide improved how well the body's insulin worked at baseline conditions after 26 weeks.
Peptide
Liraglutide
Outcome
IncreaseBasal insulin action (HOMA2)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.80 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Median change in basal insulin action
35%
liraglutide
Source sentences
Summary
HOMA2 quantified a significant improvement in basal insulin action in liraglutide (35% [21%, 74%])
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once-daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks.
Summary · context
Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods.
Report a problemFND-3382246901
02HumanRandomized controlled trialEfficacy outcome
In overweight to obese adults with type 2 diabetes, liraglutide enhanced insulin secretion by a median 73% from baseline to end of treatment.
In plain wordsIn overweight or obese adults with type 2 diabetes, liraglutide increased insulin secretion after 26 weeks of treatment.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion (HOMA2)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.80 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Median change in insulin secretion
73%
liraglutide
Source sentences
Summary
while secretion enhanced both in SAR425899 (125% [63%, 228%]) and liraglutide (73% [43%, 147%])
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once-daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks.
Summary · context
Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods.
Report a problemFND-3382246902
03HumanRandomized controlled trialEfficacy outcome
In overweight to obese adults with type 2 diabetes, liraglutide significantly improved insulin sensitivity by a median 36% from baseline.
In plain wordsIn overweight or obese adults with type 2 diabetes, liraglutide improved insulin sensitivity after 26 weeks of treatment.
Peptide
Liraglutide
Outcome
IncreaseInsulin sensitivity (oral minimal model)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.80 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Median change in insulin sensitivity
36%
liraglutide
Source sentences
Summary
OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta-cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above-basal beta-cell responsiveness (139% [64%, 261%] and 69% [-15%, 120%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once-daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks.
Summary · context
Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods.
Report a problemFND-3382246903
04HumanRandomized controlled trialEfficacy outcome
In overweight to obese adults with type 2 diabetes, liraglutide significantly improved basal beta-cell responsiveness by a median 40% from baseline.
In plain wordsIn overweight or obese adults with type 2 diabetes, liraglutide improved basal beta-cell responsiveness after 26 weeks of treatment.
Peptide
Liraglutide
Outcome
IncreaseBasal beta-cell responsiveness (oral minimal model)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.80 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Median change in basal beta-cell responsiveness
40%
liraglutide
Source sentences
Summary
OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta-cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above-basal beta-cell responsiveness (139% [64%, 261%] and 69% [-15%, 120%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once-daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks.
Summary · context
Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods.
Report a problemFND-3382246904
05HumanRandomized controlled trialEfficacy outcome
In overweight to obese adults with type 2 diabetes, liraglutide significantly improved above-basal beta-cell responsiveness by a median 69% from baseline.
In plain wordsIn overweight or obese adults with type 2 diabetes, liraglutide improved above-basal beta-cell responsiveness after 26 weeks of treatment.
Peptide
Liraglutide
Outcome
IncreaseAbove-basal beta-cell responsiveness (oral minimal model)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.80 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Median change in above-basal beta-cell responsiveness
69%
liraglutide
Source sentences
Summary
OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta-cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above-basal beta-cell responsiveness (139% [64%, 261%] and 69% [-15%, 120%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once-daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks.
Summary · context
Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods.
Report a problemFND-3382246905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02973321

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Sanofin = 2962 Dec 2016 to 27 Dec 2017

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 24 Mar 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.